NCT04335357View on ClinicalTrials.gov

TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas

PHASE2UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 31, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

June 30, 2023

Conditions
Non-Functional Pituitary AdenomaPituitary Tumor, Nonfunctioning
Interventions
DRUG

TBR-760

TBR-760 is intended for SC administration. The target dose to be studied in this study is 6 mg SC given once weekly.

DRUG

Placebo

Placebo

Sponsors
All Listed Sponsors
lead

Tiburio Therapeutics

INDUSTRY

NCT04335357 - TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas | Biotech Hunter | Biotech Hunter